Ladenburg Thalmann & Co.

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), released financial results for the third quarter ended September 30, 2022. Q3 2022 Financial Highlights Research and development expenses were $5.0 million for the third quarter of 2022, including stock-based compensation of $0.5 million. General...

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) disclosed Wednesday its first-quarter net loss of $8.0 million or a loss of 20 cents per share, compared to $12.34 million in the same period of 2020 or a loss of 53 cents per share. First Quarter Highlights Cannabinoid-focused pharmaceutical company...